This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

InVentiv Clinical Solutions Expands Its Global Alliance With Partnerships In Europe, Asia And Africa

HOUSTON, May 24, 2010 (GLOBE NEWSWIRE) -- inVentiv Clinical, a division of inVentiv Health (Nasdaq:VTIV), today announced a substantive expansion of the inVentiv Clinical Global Alliance with the additions of Protech Pharmaservices Corporation (PPC), Ecron Acunova and RDDA. These partners, along with ActivaCRO, will broaden inVentiv Clinical Solutions' clinical research capabilities in Latin America, Asia, Europe and Africa and provide CRO service coverage in more than 50 countries.

PPC ( ) is inVentiv Clinical's Asia Pacific partner with its headquarters located in Taiwan. With vast clinical experience across Asia, PPC is renowned in major countries of clinical interest such as Taiwan, Japan, China, Korea, Hong Kong, Singapore, Malaysia and Australia. PPC is dedicated to serving the pharmaceutical, biotechnology, generic drug and medical device industries with a full spectrum of drug development solutions, including phase I - IV clinical study management, bioavailability / bioequivalence studies, central laboratory, data management and statistical analysis.

Ecron Acunova ( ), inVentiv Clinical's partner for Europe, has its European headquarters in Frankfurt, Germany and operations across Europe, Asia and the Americas. With 23 years of clinical expertise, Ecron Acunova provides end-to-end services for phase I - IV clinical research, including clinical trial management, clinical data management, PK/PD services and central lab for pharmaceutical, biotech, nutritional, medical diagnostic and device sponsors. Ecron Acunova has existing relationships with several members of the Global Alliance, including an ongoing collaboration with Essential CRO, which was acquired by inVentiv Clinical early 2010, and a prior partnership with PPC in Taiwan.

RDDA ( ), inVentiv Clinical's African partner, is a contract research organization based in Pretoria, South Africa and was founded by three partners with a vision to provide the international pharmaceutical industry with expert services in clinical trials in Africa. RDDA provides regulatory, project management and monitoring support across Africa including South Africa, Namibia, Botswana, Zambia, Kenya, Mozambique and Zimbabwe.

"We are very pleased to welcome PPC, Ecron Acunova and RDDA to the inVentiv Clinical Global Alliance, which already includes ActivaCRO in Latin America ( ). The expansion of our alliance is consistent with our mission to help clients accelerate quality clinical research in a cost-effective manner," comments Michael Hlinak, President and CEO of inVentiv Clinical. "By forging alliances with these first-class partners, we are better positioned to provide our clients the unique, flexible solutions and unmatched quality they have come to expect from inVentiv Clinical, but on a global scale where it is needed today. Furthermore, this Global Alliance represents significant operational integration and access to rapidly developing clinical research markets."

"We are pleased to offer our delivery capabilities in Western and Eastern European countries, including Ukraine and Russia, and to the partners in the inVentiv Clinical network," said D A Prasanna, Founder and Vice Chairman of Ecron Acunova. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AAPL $129.99 -0.33%
FB $79.28 -1.40%
GOOG $561.76 1.10%
TSLA $203.24 -1.90%
YHOO $44.32 -0.29%


DOW 18,199.62 -14.80 -0.08%
S&P 500 2,111.13 +0.39 0.02%
NASDAQ 4,980.4690 -7.4210 -0.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs